Sign In
Buy ORIC
$8.93
+0.440 (+5.18%)
At Close: Jun 22, 2026
Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade
10:56am, Thursday, 26'th Feb 2026
The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 58.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
04:05pm, Monday, 23'rd Feb 2026
Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization i
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
05:14pm, Wednesday, 18'th Feb 2026
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 06'th Feb 2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address m
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
04:01pm, Thursday, 05'th Feb 2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Short Interest Update
04:53am, Wednesday, 21'st Jan 2026
Oric Pharmaceuticals, Inc. (NASDAQ: ORIC - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest total
ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside
01:36pm, Tuesday, 20'th Jan 2026
ORIC Pharmaceuticals is advancing two best-in-class small molecule inhibitors targeting resistance mechanisms in prostate and lung cancer. ORIC's $413 million cash position, bolstered by a 2025 equity
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
10:52am, Wednesday, 14'th Jan 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion
ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:35pm, Tuesday, 13'th Jan 2026
ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
08:30am, Monday, 12'th Jan 2026
Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combin
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 06'th Jan 2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 05'th Dec 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address m
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
01:00am, Friday, 05'th Dec 2025
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development pl
